Investment Opportunity: Fc-Engager Immune Tolerance Platform

LoopLab Bio is pioneering the development of a first-in-class Fc-Engager platform, a novel therapeutic approach designed to establish durable, antigen-specific immune tolerance. By selectively engaging inhibitory Fc receptors together with disease-related antigens, our biologics aim to retrain the immune system, offering the potential for safer and longer-lasting treatments than current broad immunosuppressive therapies.

We are now seeking Series A investment of €30–50M to:

• Advance lead Fc-Engager programs toward IND submission by 2027

• Initiate first-in-human studies in 2028

• Strengthen CMC, GMP manufacturing, and regulatory readiness

• Expand the exploratory pipeline in autoimmune disease, ADA prevention, allergy, transplant tolerance, and rare metabolic disorders

Why invest in LoopLab Bio?

• Strong financing base: Independently funded until 2027, providing a de-risked entry point

• Robust IP: Platform and candidates protected by proprietary engineering and patents

• Early validation: Supported by in vitro, ex vivo, and in vivo humanized models

• Expansive market: >€200B opportunity across immune tolerance indications

• Experienced team: Proven biotech/pharma leadership and global advisory network

We warmly welcome investment partners who share our vision of advancing safe, durable, and patient-focused immune tolerance therapies.